vs
Caris Life Sciences, Inc.（CAI）与EXACT SCIENCES CORP（EXAS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Caris Life Sciences, Inc.的4.1倍（$878.4M vs $216.8M）。Caris Life Sciences, Inc.净利率更高（11.2% vs -9.8%，领先21.0%）。Caris Life Sciences, Inc.同比增速更快（113.4% vs 23.1%）。EXACT SCIENCES CORP自由现金流更多（$120.4M vs $55.3M）
Caris生命科学是一家领先的精准医疗生物技术企业，专注于肿瘤领域的先进分子检测服务，为肿瘤医生提供可落地的基因组与分子层面洞察以制定个性化癌症治疗方案，同时与生物制药企业合作加速抗癌新药研发，业务覆盖北美、欧洲及亚太主要市场。
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
CAI vs EXAS — 直观对比
营收规模更大
EXAS
是对方的4.1倍
$216.8M
营收增速更快
CAI
高出90.3%
23.1%
净利率更高
CAI
高出21.0%
-9.8%
自由现金流更多
EXAS
多$65.1M
$55.3M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $216.8M | $878.4M |
| 净利润 | $24.3M | $-86.0M |
| 毛利率 | — | 70.1% |
| 营业利润率 | 15.1% | -9.4% |
| 净利率 | 11.2% | -9.8% |
| 营收同比 | 113.4% | 23.1% |
| 净利润同比 | 135.9% | 90.1% |
| 每股收益（稀释后） | $0.08 | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CAIEXAS
| Q4 25 | — | $878.4M | ||
| Q3 25 | $216.8M | $850.7M | ||
| Q2 25 | $181.4M | $811.1M | ||
| Q1 25 | — | $706.8M | ||
| Q4 24 | — | $713.4M | ||
| Q3 24 | $101.6M | $708.7M | ||
| Q2 24 | $100.0M | $699.3M | ||
| Q1 24 | — | $637.5M |
净利润CAIEXAS
| Q4 25 | — | $-86.0M | ||
| Q3 25 | $24.3M | $-19.6M | ||
| Q2 25 | $-71.8M | $-1.2M | ||
| Q1 25 | — | $-101.2M | ||
| Q4 24 | — | $-864.6M | ||
| Q3 24 | $-67.7M | $-38.2M | ||
| Q2 24 | $-66.2M | $-15.8M | ||
| Q1 24 | — | $-110.2M |
毛利率CAIEXAS
| Q4 25 | — | 70.1% | ||
| Q3 25 | — | 68.6% | ||
| Q2 25 | — | 69.3% | ||
| Q1 25 | — | 70.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 69.4% | ||
| Q2 24 | — | 69.8% | ||
| Q1 24 | — | 70.0% |
营业利润率CAIEXAS
| Q4 25 | — | -9.4% | ||
| Q3 25 | 15.1% | -3.0% | ||
| Q2 25 | -9.9% | -0.3% | ||
| Q1 25 | — | -13.6% | ||
| Q4 24 | — | -122.8% | ||
| Q3 24 | -59.9% | -5.6% | ||
| Q2 24 | -67.0% | -3.8% | ||
| Q1 24 | — | -16.7% |
净利率CAIEXAS
| Q4 25 | — | -9.8% | ||
| Q3 25 | 11.2% | -2.3% | ||
| Q2 25 | -39.6% | -0.1% | ||
| Q1 25 | — | -14.3% | ||
| Q4 24 | — | -121.2% | ||
| Q3 24 | -66.6% | -5.4% | ||
| Q2 24 | -66.2% | -2.3% | ||
| Q1 24 | — | -17.3% |
每股收益（稀释后）CAIEXAS
| Q4 25 | — | $-0.45 | ||
| Q3 25 | $0.08 | $-0.10 | ||
| Q2 25 | $-7.97 | $-0.01 | ||
| Q1 25 | — | $-0.54 | ||
| Q4 24 | — | $-4.69 | ||
| Q3 24 | $-2.59 | $-0.21 | ||
| Q2 24 | $-2.54 | $-0.09 | ||
| Q1 24 | — | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $755.5M | $964.7M |
| 总债务越低越好 | $375.9M | — |
| 股东权益账面价值 | $478.4M | $2.4B |
| 总资产 | $984.6M | $5.9B |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资CAIEXAS
| Q4 25 | — | $964.7M | ||
| Q3 25 | $755.5M | $1.0B | ||
| Q2 25 | $721.2M | $858.4M | ||
| Q1 25 | — | $786.2M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $946.8M | ||
| Q1 24 | — | $652.1M |
总债务CAIEXAS
| Q4 25 | — | — | ||
| Q3 25 | $375.9M | — | ||
| Q2 25 | $373.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CAIEXAS
| Q4 25 | — | $2.4B | ||
| Q3 25 | $478.4M | $2.5B | ||
| Q2 25 | $452.9M | $2.5B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | $-2.4B | $3.2B | ||
| Q2 24 | $-2.4B | $3.2B | ||
| Q1 24 | — | $3.1B |
总资产CAIEXAS
| Q4 25 | — | $5.9B | ||
| Q3 25 | $984.6M | $5.9B | ||
| Q2 25 | $955.1M | $5.8B | ||
| Q1 25 | — | $5.7B | ||
| Q4 24 | — | $5.9B | ||
| Q3 24 | — | $6.7B | ||
| Q2 24 | — | $6.7B | ||
| Q1 24 | — | $6.4B |
负债/权益比CAIEXAS
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $62.4M | $151.7M |
| 自由现金流经营现金流 - 资本支出 | $55.3M | $120.4M |
| 自由现金流率自由现金流/营收 | 25.5% | 13.7% |
| 资本支出强度资本支出/营收 | 3.3% | 3.6% |
| 现金转化率经营现金流/净利润 | 2.57× | — |
| 过去12个月自由现金流最近4个季度 | — | $356.8M |
8季度趋势，按日历期对齐
经营现金流CAIEXAS
| Q4 25 | — | $151.7M | ||
| Q3 25 | $62.4M | $219.9M | ||
| Q2 25 | — | $89.0M | ||
| Q1 25 | — | $30.8M | ||
| Q4 24 | — | $47.1M | ||
| Q3 24 | — | $138.7M | ||
| Q2 24 | — | $107.1M | ||
| Q1 24 | — | $-82.3M |
自由现金流CAIEXAS
| Q4 25 | — | $120.4M | ||
| Q3 25 | $55.3M | $190.0M | ||
| Q2 25 | — | $46.7M | ||
| Q1 25 | — | $-365.0K | ||
| Q4 24 | — | $10.7M | ||
| Q3 24 | — | $112.6M | ||
| Q2 24 | — | $71.2M | ||
| Q1 24 | — | $-120.0M |
自由现金流率CAIEXAS
| Q4 25 | — | 13.7% | ||
| Q3 25 | 25.5% | 22.3% | ||
| Q2 25 | — | 5.8% | ||
| Q1 25 | — | -0.1% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | — | 15.9% | ||
| Q2 24 | — | 10.2% | ||
| Q1 24 | — | -18.8% |
资本支出强度CAIEXAS
| Q4 25 | — | 3.6% | ||
| Q3 25 | 3.3% | 3.5% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 5.1% | ||
| Q1 24 | — | 5.9% |
现金转化率CAIEXAS
| Q4 25 | — | — | ||
| Q3 25 | 2.57× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAI
| Molecular Profiling Services | $207.6M | 96% |
| Pharma Research And Development Services | $9.2M | 4% |
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
